Stellaromics, founded in Natick, Massachusetts, is a biotechnology company dedicated to advancing biomedical research through its cutting-edge 3D in situ multi-omic analysis technology. The company's core mission is to empower researchers and clinicians by providing high-resolution, spatially preserved gene expression data from thick tissue samples. This innovative approach aims to revolutionize the understanding of complex biological systems and disease mechanisms, with a focus on enhancing precision medicine and therapeutic development.

Stellaromics has garnered significant attention and investment, securing $25 million in Series A funding. The company is led by a team of experts in biotechnology and software development, whose combined expertise drives its technological advancements. Stellaromics' achievements include developing one of the most powerful tools for 3D multi-omic analysis, which has the potential to make a substantial impact on biomedical research and healthcare. By enabling more detailed and accurate tissue analysis, Stellaromics is poised to contribute significantly to the future of personalized medicine.